A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

NCT ID: NCT01347710

Last Updated: 2020-11-24

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

795 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography (SPECT) MPI in the detection of significant coronary artery disease (CAD) as defined by invasive coronary angiography (ICA) or a documented history of Myocardial Infarction (MI).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will assess the diagnostic efficacy (sensitivity and specificity) of Flurpiridaz F18 Injection MPI against SPECT MPI in patients screened for CAD as determined by ICA. Six hundred and eighty evaluable patients will be enrolled and will undergo SPECT MPI and Flurpiridaz F18 PET MPI. Patients will be considered for enrollment if they are scheduled to undergo or have undergone prior ICA without intervention (being either positive or negative for CAD).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Coronary Artery Disease. Positron Emission Tomography Myocardial Perfusion Imaging. Single Positron Emission Computed Tomography. Flurpiridaz F18 Injection.

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Flurpiridaz F18

Open-label study of a single dose of Flurpiridaz F18 injection for PET MPI compared to a single dose of 99mTc sestamibi or tetrofosmin for SPECT MPI in patients with suspected or known coronary artery disease referred for coronary catheterization

Group Type EXPERIMENTAL

Flurpiridaz F18

Intervention Type DRUG

Injection of Flurpiridaz F18 for the purposes of PET myocardial profusion imaging (MPI) analysis

99mTechnicium (sestamibi or tetrofosmin)

Intervention Type DRUG

Injection of 99mTc sestamibi or tetrofosmin for the purposes of SPECT MPI analysis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Flurpiridaz F18

Injection of Flurpiridaz F18 for the purposes of PET myocardial profusion imaging (MPI) analysis

Intervention Type DRUG

99mTechnicium (sestamibi or tetrofosmin)

Injection of 99mTc sestamibi or tetrofosmin for the purposes of SPECT MPI analysis

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

flurpiridaz F 18 99mTc sestamibi or 99mTc Tetrofosmin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Invasive Coronary Angiography. Men or Women age 18 or older - see protocol for additional details.

Exclusion Criteria

Women who are pregnant, lactating, or of child bearing potential who are not practicing birth control.

Unstable cardiac status. History of coronary artery bypass graft. History of percutaneous coronary intervention within the past six months. See protocol for additional details.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lantheus Medical Imaging

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cesare Orlandi, MD

Role: STUDY_DIRECTOR

Lantheus Medical Imaging

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiology Associates of Mobile, Inc.

Mobile, Alabama, United States

Site Status

Scottsdale Medical Imaging, Ltd.

Scottsdale, Arizona, United States

Site Status

West Side Medical Associates of Los Angeles

Beverly Hills, California, United States

Site Status

USC PET Imaging Science Center

Los Angeles, California, United States

Site Status

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

VA West Los Angeles Medical Center

Los Angeles, California, United States

Site Status

UCLA

Los Angeles, California, United States

Site Status

Veterans Affairs Palo Alto Health Care System

Palo Alto, California, United States

Site Status

Cardiovascular Consultants Medical Group

Pleasant Hill, California, United States

Site Status

Northern California PET Imaging Center-Palo Alto

Sacramento, California, United States

Site Status

VA San Diego Healthcare System

San Diego, California, United States

Site Status

UCSF Medical Center

San Francisco, California, United States

Site Status

Yale University

New Haven, Connecticut, United States

Site Status

Alfieri Cardiology

Newark, Delaware, United States

Site Status

Christiana Care Health System

Newark, Delaware, United States

Site Status

Elite Research and Clinical Trials

Aventura, Florida, United States

Site Status

Independent Imaging, LLC

Boynton Beach, Florida, United States

Site Status

Coastal Cardiology Consultants dba The Heart & Vascular Institute of Florida

Clearwater, Florida, United States

Site Status

Florida Heart Associates

Fort Myers, Florida, United States

Site Status

St. Luke's Cardiology Associates

Jacksonville, Florida, United States

Site Status

The Cardiovascular Center, PA

Lake Mary, Florida, United States

Site Status

Florida Hospital/Cardiovascular Institute (Florida Heart Group)

Orlando, Florida, United States

Site Status

South Florida Research Solutions

Pembroke Pines, Florida, United States

Site Status

Memorial Hospital of Tampa

Tampa, Florida, United States

Site Status

Georgia Health Sciences Univ/Med College of GA

Augusta, Georgia, United States

Site Status

South Coast Imaging Center

Savannah, Georgia, United States

Site Status

Gateway Cardiology, PC

Jerseyville, Illinois, United States

Site Status

Norton Cardiovascular Associates

Louisville, Kentucky, United States

Site Status

Biomedical Research Foundation of Northwest Louisiana

Shreveport, Louisiana, United States

Site Status

Maine Research Associates

Auburn, Maine, United States

Site Status

Johns Hopkins University

Baltimore, Maryland, United States

Site Status

Mass General Hospital (MGH)

Boston, Massachusetts, United States

Site Status

Boston University Medical Center

Boston, Massachusetts, United States

Site Status

University of Michigan Health System

Ann Arbor, Michigan, United States

Site Status

Wayne State University - Harper University Hospital

Detroit, Michigan, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

St. Mary's Healthcare (Trinity Health)

Grand Rapids, Michigan, United States

Site Status

McLaren Macomb

Mount Clemens, Michigan, United States

Site Status

William Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

Hattiesburg Clinic

Hattiesburg, Mississippi, United States

Site Status

Missouri Cardiovascular Specialists, LLP

Columbia, Missouri, United States

Site Status

Cardiovascular Imaging Technologies (CVIT)

Kansas City, Missouri, United States

Site Status

Saint Louis University School of Medicine

St Louis, Missouri, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Las Vegas Radiology

Las Vegas, Nevada, United States

Site Status

Mount Sinai Medical Center

New York, New York, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

St. Francis Hospital

Roslyn, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

The Ohio State University

Columbus, Ohio, United States

Site Status

OhioHealth Research Institute

Columbus, Ohio, United States

Site Status

Kettering Medical Center

Kettering, Ohio, United States

Site Status

Pinnacle Health Cardiovascular Institute/ Associated Cardiologists

Harrisburg, Pennsylvania, United States

Site Status

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Presbyterian University Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Berks Cardiologists, Ltd.

Wyomissing, Pennsylvania, United States

Site Status

York Hospital /Wellspan Health

York, Pennsylvania, United States

Site Status

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Wellmont CVA Heart Institute

Kingsport, Tennessee, United States

Site Status

Center for Biomedical Research

Knoxville, Tennessee, United States

Site Status

Cardiovascular Research of Knoxville - St. Mary's Health Care System, Inc.

Knoxville, Tennessee, United States

Site Status

Vanderbilt Heart and Vascular Institute

Nashville, Tennessee, United States

Site Status

Dallas VA Medical Center

Dallas, Texas, United States

Site Status

University of Texas Medical Branch

Galveston, Texas, United States

Site Status

Excel Diagnostics and Nuclear Oncology Center

Houston, Texas, United States

Site Status

Katy Cardiology

Katy, Texas, United States

Site Status

West Houston Area Clinical Trial Consultants, LLC

Tomball, Texas, United States

Site Status

University of Virginia Health System

Charlottesville, Virginia, United States

Site Status

McGuire Veteran Affairs Medical Center

Richmond, Virginia, United States

Site Status

Carilion Cardiology Clinic

Roanoke, Virginia, United States

Site Status

Roanoke Heart Institute

Roanoke, Virginia, United States

Site Status

University of Western Ontario

London, Ontario, Canada

Site Status

KMH Cardiology and Diagnostic and MRI Centres

Mississauga, Ontario, Canada

Site Status

University of Ottawa Heart Institute

Ottawa, Ontario, Canada

Site Status

Centre Hospitalier Universitaire de Sherbrooke (CHUS)

Sherbrooke, Quebec, Canada

Site Status

Helsinki University Hospital

Helsinki, , Finland

Site Status

Turku PET Centre

Turku, , Finland

Site Status

San Patricio MEDFLIX (San Patricio MRI & CT Center)

Guaynabo, , Puerto Rico

Site Status

VA Caribbean Healthcare System

San Juan, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Finland Puerto Rico

References

Explore related publications, articles, or registry entries linked to this study.

Lopez DM, Huck D, Divakaran S, Brown JM, Weber B, Lemley M, Builoff V, Shanbhag A, Lan Z, Buckley C, Al-Mallah MH, Dorbala S, Blankstein R, Slomka P, Di Carli MF. Utility of 18F-Flurpiridaz PET Relative Flow Reserve in Differentiating Obstructive From Nonobstructive Coronary Artery Disease. Circ Cardiovasc Imaging. 2025 Oct 9:e018323. doi: 10.1161/CIRCIMAGING.125.018323. Online ahead of print.

Reference Type DERIVED
PMID: 41064867 (View on PubMed)

Poitrasson-Riviere A, Moody JB, Renaud JM, Hagio T, Arida-Moody L, Buckley CJ, Al-Mallah MH, Nallamothu BK, Weinberg RL, Ficaro EP, Murthy VL. Integrated myocardial flow reserve (iMFR) assessment: optimized PET blood flow quantification for diagnosis of coronary artery disease. Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):136-146. doi: 10.1007/s00259-023-06455-2. Epub 2023 Oct 9.

Reference Type DERIVED
PMID: 37807004 (View on PubMed)

Hagio T, Moody JB, Poitrasson-Riviere A, Renaud JM, Pierce L, Buckley C, Ficaro EP, Murthy VL. Multi-center, multi-vendor validation of deep learning-based attenuation correction in SPECT MPI: data from the international flurpiridaz-301 trial. Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1028-1033. doi: 10.1007/s00259-022-06045-8. Epub 2022 Nov 19.

Reference Type DERIVED
PMID: 36401636 (View on PubMed)

Maddahi J, Lazewatsky J, Udelson JE, Berman DS, Beanlands RSB, Heller GV, Bateman TM, Knuuti J, Orlandi C. Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease. J Am Coll Cardiol. 2020 Jul 28;76(4):391-401. doi: 10.1016/j.jacc.2020.05.063.

Reference Type DERIVED
PMID: 32703509 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BMS747158-301

Identifier Type: -

Identifier Source: org_study_id